Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
PAREMYD is a fixed-dose ophthalmic combination of hydroxyamphetamine hydrobromide and tropicamide in drop form, used for mydriasis (pupil dilation) during diagnostic eye examinations. Hydroxyamphetamine is an indirect-acting sympathomimetic that releases norepinephrine, while tropicamide is an anticholinergic agent that blocks acetylcholine; together they produce rapid and sustained pupil dilation for ophthalmologic procedures.
As an older NDA approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely consolidating around retention and efficiency rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PAREMYD offers exposure to lifecycle management and competitive defense in the ophthalmic space, but limited growth trajectory. This is a stabilization role suited to professionals skilled in efficiency, cost management, and transition planning rather than launch or expansion.
Worked on PAREMYD at Epic Pharma Llc? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.